Vimarsana
Biggest News Aggregation in the World

Page 20 - Arix Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arix Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arix Bioscience Today - Breaking & Trending Today

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Board Change - Vimarsana News

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Board Change

Investegate announcements from Arix Bioscience PLC, Board Change

Biotech Financing Roundup: Belharra, NextPoint, Pathalys & More - Vimarsana News

Biotech Financing Roundup: Belharra, NextPoint, Pathalys & More

Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.

Ensoma Raises $85M in Series B Funding; Acquires Twelve Bio - Vimarsana News

Ensoma Raises $85M in Series B Funding; Acquires Twelve Bio

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy p - Vimarsana News

Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy p

Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform  London, UK, 5 January 2023 – Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company fo...

Ensoma buys a startup to advance 'in vivo' cell therapy work - Vimarsana News

Ensoma buys a startup to advance 'in vivo' cell therapy work

BioPharma